Impact of skeletal muscle mass in patients with recurrent gastric cancer.

Tomoyuki MatsunagaHiroaki SatioWataru MiyauchiYuji ShishidoKozo MiyataniYuki MurakamiTakehiko HanakiKyoichi KiharaManabu YamamotoNaruo TokuyasuShuichi TakanoTeruhisa SakamotoToshimichi HasegawaYoshiyuki Fujiwara

Published in: World journal of surgical oncology (2021)

The incidence of grade 3 or 4 side effects was significantly higher in patients with SMILow RGC. SMI was a useful prognostic marker of RGC.

Keyphrases

skeletal muscle
risk factors
insulin resistance
metabolic syndrome